HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.


Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 27 4 2021
medline: 3 2 2022
entrez: 26 4 2021
Statut: ppublish

Résumé

Justice-involved (JI) populations bear a disproportionate burden of HIV infection and are at risk of poor treatment outcomes. Drug resistance prevalence and emergence, and phylogenetic inference of transmission networks, understudied in vulnerable JI populations, can inform care and prevention interventions, particularly around the critical community reentry period. We analyzed banked blood specimens from CARE+ Corrections study participants in Washington, D.C. (DC) across three time points and conducted HIV drug resistance testing using next-generation sequencing (NGS) at 20% and 5% thresholds to identify prevalent and evolving resistance during community reentry. Phylogenetic analysis was used to identify molecular clusters within participants, and in an extended analysis between participants and publicly available DC sequences. HIV sequence data from 54 participants (99 specimens) were analyzed. The prevalence of transmitted drug resistance was 14% at both thresholds, and acquired drug resistance was 47% at 20%, and 57% at 5% NGS thresholds, respectively. The overall prevalence of drug resistance was 43% at 20%, and 52% at 5% NGS thresholds, respectively. Among 34 participants sampled longitudinally, 21%-35% accumulated 10-17 new resistance mutations during a mean 4.3 months. In phylogenetic analysis within the JI population, 11% were found in three molecular clusters. The extended phylogenetic analysis identified 46% of participants in 22 clusters, of which 21 also included publicly-available DC sequences, and one JI-only unique dyad. This is the first study to identify a high prevalence of HIV drug resistance and its accumulation in a JI population during community reentry and suggests phylogenetic integration of this population into the non-JI DC HIV community. These data support the need for new, effective, and timely interventions to improve HIV treatment during this vulnerable period, and for JI populations to be included in broader surveillance and prevention efforts.

Identifiants

pubmed: 33896212
doi: 10.1089/AID.2020.0267
pmc: PMC8716515
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

903-912

Subventions

Organisme : NIAID NIH HHS
ID : R25 AI140490
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI117970
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA030747
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI134359
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States

Références

BMC Public Health. 2009 May 27;9:156
pubmed: 19473508
JAMA Intern Med. 2018 Apr 1;178(4):542-553
pubmed: 29532059
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
HIV Med. 2017 Nov;18(10):756-763
pubmed: 28585361
PLoS One. 2018 Mar 30;13(3):e0191643
pubmed: 29601591
Sci Rep. 2020 Oct 29;10(1):18547
pubmed: 33122765
PLoS One. 2009;4(5):e5416
pubmed: 19412547
N Engl J Med. 2010 Mar 18;362(11):967-70
pubmed: 20147707
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
Clin Infect Dis. 2017 Oct 1;65(7):1247-1248
pubmed: 28549121
AIDS Behav. 2011 Feb;15(2):356-64
pubmed: 21042930
PLoS One. 2017 Jan 12;12(1):e0169078
pubmed: 28081178
J Clin Microbiol. 2018 May 25;56(6):
pubmed: 29618499
AIDS Behav. 2019 Apr;23(4):1016-1031
pubmed: 30627850
HIV Clin Trials. 2008 Sep-Oct;9(5):341-7
pubmed: 18977723
Viruses. 2015 Dec 07;7(12):6360-70
pubmed: 26690199
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71
pubmed: 22135472
Lancet HIV. 2018 Nov;5(11):e638-e646
pubmed: 30282603
AIDS Res Hum Retroviruses. 2013 Jan;29(1):136-41
pubmed: 22966822
Antivir Ther. 2012;17(2):377-86
pubmed: 22297391
HIV Clin Trials. 2011 Sep-Oct;12(5):244-54
pubmed: 22180522
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
J Offender Rehabil. 2012 Jan;51(1-2):78-95
pubmed: 23087588
PLoS One. 2009;4(3):e4724
pubmed: 19266092
Am J Public Health. 2015 Jul;105(7):e5-16
pubmed: 25973818
Bioinformatics. 2019 Jun 1;35(12):2029-2035
pubmed: 30407489
AIDS Res Hum Retroviruses. 2012 Feb;28(2):171-5
pubmed: 21819219
Clin Infect Dis. 2002 Oct 1;35(7):883-6
pubmed: 12228827
J Antimicrob Chemother. 2020 Jan 1;75(1):170-182
pubmed: 31617907
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
PLoS One. 2009 Nov 11;4(11):e7558
pubmed: 19907649
PLoS One. 2013 Jul 09;8(7):e69033
pubmed: 23874857
AIDS Res Hum Retroviruses. 2011 Dec;27(12):1349-53
pubmed: 21732793
Annu Rev Med. 2019 Jan 27;70:137-150
pubmed: 30355266
J Infect Dev Ctries. 2014 Aug 13;8(8):1063-7
pubmed: 25116676
BMC Res Notes. 2017 Sep 11;10(1):474
pubmed: 28893321
J Antimicrob Chemother. 2015 Jul;70(7):2090-6
pubmed: 25755001
Viruses. 2020 Jun 27;12(7):
pubmed: 32605062
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):543-550
pubmed: 30222659
Public Health Rep. 2005 Jan-Feb;120(1):84-8
pubmed: 15736336
JAMA. 2009 Feb 25;301(8):848-57
pubmed: 19244192
J Infect Dis. 2017 Dec 1;216(suppl_9):S820-S823
pubmed: 29029155

Auteurs

Curt G Beckwith (CG)

Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Sugi Min (S)

The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Akarsh Manne (A)

Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Vladimir Novitsky (V)

Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Mark Howison (M)

Research Improving People's Lives, Providence, Rhode Island, USA.

Tao Liu (T)

Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island, USA.

Irene Kuo (I)

George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA.

Ann Kurth (A)

Yale University School of Nursing, Orange, Connecticut, USA.

Lauri Bazerman (L)

Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.

Anya Agopian (A)

George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA.

Rami Kantor (R)

Division of Infectious Diseases, The Miriam Hospital, Providence, Rhode Island, USA.
The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH